Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation.

ABSTRACT:

Background

Anemia is encountered in patients with nonvalvular atrial fibrillation (NVAF) on oral anticoagulants (OACs) but the prognostic impact was not well scrutinized in real-world settings.

Methods

We conducted a historical multicenter registry of patients with NVAF taking OACs at 71 centers in Japan. Those with mechanical heart valves or a history of pulmonary thrombosis or deep venous thrombosis were excluded. Anemic patients were divided into three groups of hemoglobin (Hb) level: moderate/severe (Hb < 11.0 g/dL), mild (men: Hb of 11.0-12.9 g/dL; women: Hb of 11.0-11.9 g/dL), and no anemia. The endpoints included major bleeding, hemorrhagic stroke, ischemic events, ischemic stroke, and all-cause mortality.

Results

Among 7558 consecutive patients (mean age, 73 y

SUBMITTER: Kinjo N 

PROVIDER: S-EPMC10407181 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature